Opus GeneticsIRD -9.18%24 Current Ratio is 7.13 as of Mar. 2026, which is 8% above its 10-year median of 6.63. GuruFocus rates IRD with a GF Score™ of 24/100 and a GF Value™ of $0.37 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,417 Biotechnology companies, Opus Genetics ranks better than 69.3% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Opus Genetics's current ratio for the quarter that ended in Mar. 2026 was 7.13.
Opus Genetics has a current ratio of 7.13. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Opus Genetics's Current Ratio or its related term are showing as below:
IRD'
s Current Ratio Range Over the Past 10 Years
Min: 0.19 Med: 6.63 Max: 17.79
Current: 7.13
During the past 7 years, Opus Genetics's highest Current Ratio was 17.79. The lowest was 0.19. And the median was 6.63.
IRD's Current Ratio is ranked better than 69.3% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs IRD: 7.13
Opus Genetics (NAS:IRD) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Opus Genetics Current Ratio Related Terms
Opus Genetics Current Ratio Historical Data
* Premium members only.
The historical data trend for Opus Genetics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Opus Genetics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Opus Genetics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Opus Genetics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Opus Genetics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Opus Genetics (IRD) has a Current Ratio of 7.13 as of Mar. 2026. This is near median its historical median of 6.63. Over the past decade, Opus Genetics' Current Ratio has ranged from 0.19 to 17.79. According to the industry distribution chart, Opus Genetics ranks #435 out of 1417 companies in the Biotechnology industry, placing it in the top 30.7%.
Is Opus Genetics' Current Ratio too high?
Opus Genetics' current Current Ratio of 7.13 is near median its 10-year median of 6.63. Over the past 10 years, this metric has ranged from a low of 0.19 to a high of 17.79. The Biotechnology industry median Current Ratio is 3.89. Opus Genetics' value of 7.13 is 83.3% above this industry median. Based on the distribution chart, Opus Genetics ranks #435 out of 1417 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Opus Genetics has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Opus Genetics' Current Ratio compare to IFRX and RGNX?
According to the Biotechnology industry distribution chart, Opus Genetics ranks #435 out of 1417 companies for Current Ratio. This puts Opus Genetics in the upper half of its industry. The industry median Current Ratio is 3.89. Opus Genetics' value of 7.13 is 83.3% above this benchmark. Historically, Opus Genetics' own Current Ratio has ranged from 0.19 to 17.79 over the past decade. While the company's 10-year median is 6.63 vs. the industry median of 3.89, Opus Genetics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Opus Genetics's current Current Ratio of 7.13 is 83.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Opus Genetics's current Current Ratio is 7.13, which is near median its own 10-year median of 6.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opus Genetics stock overvalued right now?
Based on GuruFocus' analysis, Opus Genetics (IRD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.37, compared to a current price of $3.71 — trading 901.4% above its estimated fair value. The current Current Ratio is 7.13, which is near median its 10-year median of 6.63 and 83.3% above the Biotechnology industry median of 3.89. Opus Genetics' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Opus Genetics (IRD), the current Current Ratio is 7.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Opus Genetics (IRD) Overvalued in 2026?
Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued.
The current stock price of $3.71 is trading 901.4% above its estimated GF Value™ of $0.37.
GuruFocus considers Opus Genetics to be Significantly Overvalued.
Key valuation signals for IRD:
Current Ratio: 7.13 (near median its 10-year median of 6.63)
GF Value™: $0.37 vs. price of $3.71 (901.4% above fair value)
Industry Position: 83.3% above the Biotechnology median (#435 of 1417)
No single metric tells the full story. See the IRD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
24GF Score
Get the complete analysis for IRD
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRD has been successfully added to your 
